Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44 results about "Malignant Glomus Tumor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A very rare morphologic variant of glomus tumor with a size greater than 2 cm. The tumor arises in subfascial or visceral tissues. It is characterized by the presence of atypical mitotic figures, or marked nuclear atypia, or the combination of both. It has an aggressive clinical course.
System and method for automated segmentation, characterization, and classification of possibly malignant lesions and stratification of malignant tumors
A method and apparatus for classifying possibly malignant lesions from sets of DCE-MRI images includes receiving a set of MRI slice images obtained at respectively different times, where each slice image includes voxels representative of at least one region of interest (ROI). The images are processed to determine the boundaries of the ROIs and the voxels within the identified boundaries in corresponding regions of the images from each time period are processed to extract kinetic texture features. The kinetic texture features are then used in a classification process which classifies the ROIs as malignant or benign. The malignant lesions are further classified to separate TN lesions from non-TN lesions.
Owner:RUTGERS THE STATE UNIV
System and method for automated segmentation, characterization, and classification of possibly malignant lesions and stratification of malignant tumors
A method and apparatus for classifying possibly malignant lesions from sets of DCE-MRI images includes receiving a set of MRI slice images obtained at respectively different times, where each slice image includes voxels representative of at least one region of interest (ROI). The images are processed to determine the boundaries of the ROIs and the voxels within the identified boundaries in corresponding regions of the images from each time period are processed to extract kinetic texture features. The kinetic texture features are then used in a classification process which classifies the ROIs as malignant or benign. The malignant lesions are further classified to separate TN lesions from non-TN lesions.
Owner:RUTGERS THE STATE UNIV
Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth.
Owner:EXOSOMICS SIENA SPA
Gene chip for gynecologic malignant tumor early screening and detection method thereof
InactiveCN101230390AClear functionEasy to sampleMicrobiological testing/measurementMortality rateOvarian cancer
The invention provides a method of manufacturing an oligonucleotide gene chip for screening and diagnosing the normally gynecological malignant tumor in early phase and the method of detecting the same. The method uses the related genes of normally gynecological malignant tumor (breast cancer, ovarian cancer and uterine cancer) as control, and determines whether the patient has the malignant tumor by manufacturing the oligonucleotide and chip hybridizing and detecting. The invention provides a detecting method of screening and diagnosing the normally gynecological malignant tumor in early phase based on gene chip, which makes the characteristic gene of the normally gynecological malignant tumor into a gene chip so as to keep the consistence of the clinic detecting condition. The method can screen and diagnose the normally malignant tumor ASAP. With convenience in sampling and good consistence, the method of the invention is prone to popularize; by proper application, the cancer mortality can be reduced by 1 / 3.
Owner:HUBEI UNIV
Specific peptide binding to glypican-3
A specific targeting peptide binding to glypican-3 can specifically binds to glypican-3 overexpressed in carcinoma cells and includes an amino acid sequence represented by SEQ ID NO:1 or some thereof. Glypican-3 is overexpressed in malignant tumors including hepatocellular carcinoma, melanoma, germ cell tumor, etc., and may be targeted in diagnosis and treatment of tumors by labeling the targeting peptide. A diagnosis using the specific peptide may detect even small tumors more accurately than conventional methods. A treatment method using the specific peptide may remove only carcinoma cells without harming other normal tissues.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
Therapeutic vaccine for malignant tumors and composition thereof
The invention relates to a therapeutic vaccine for malignant tumors and a composition thereof. The therapeutic vaccine for malignant tumors is a tumor cell line which contains plasmid of antisense nucleic acid of human transforming growth factor beta (TGF-beta2); the therapeutic vaccine composition for malignant tumors comprises the therapeutic vaccine for malignant tumors and an immunopotentiator, and the immunopotentiator is one selected from the group consisting of a Corynebacterium parvum preparation, a non-cell Corynebacterium parvum preparation, a BCG polysaccharide, a nucleic acid preparation, a Nocardia rubra-cell wall skeleton preparation, a group A Streptococcus preparation, a non-cell group A Streptococcus preparation, a Pseudomonas aeruginosa preparation, a non-cell Pseudomonas aeruginosa preparation, a Brucella preparation, a non-cell Brucella preparation, a non-cell Mycobacterium vaccae preparation and a non-cell Mycobacterium smegmatis preparation, preferably the non-cell Corynebacterium parvum preparation; and the malignant tumors include a lung cancer, a liver cancer, a pancreatic cancer, leukemia, lymphoma, an ovarian cancer, a colon cancer, a stomach cancer and a breast cancer.
Owner:熊慧
Microsphere-gel slow-release preparation for treating malignant tumor and thoracic-celiac metastasis
InactiveCN110051624AProlong survival timePlay a sustained anti-tumor effectOrganic active ingredientsInorganic active ingredientsLymphatic SpreadSide effect
The invention discloses a microsphere-gel slow-release preparation for treating malignant tumor and thoracic-celiac metastasis. The preparation comprises a microsphere base, antitumor drug and a gel carrier for dispersing the microsphere base and the antitumor drug, the antitumor active drug is loaded on the microsphere base, loading amount of the antitumor active drug on the microsphere base is 1-50%, and a mass ratio of the microsphere base to the gel carrier is 1:3-5. The microsphere base can be segmented copolymer or homopolymer, and when the microsphere base is the segment copolymer, number-average molecular weight ratio of a hydrophobic chain segment to a hydrophilic chain segment is 1-2500. The microsphere-gel slow-release preparation which is chemotherapy drug is formed by loadingchemotherapy drug on high molecular polymer, and the preparation can generate slow-release and antitumor effects when being in-situ injected into a body; the preparation has relatively little whole-body toxic and side effect, so that better continuous treatment effect is realized.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
Owner:EXOSOMICS SIENA SPA
Polyethylene glycol-gambogic acid liposome, preparation method and application thereof in treatment of malignant tumors
ActiveCN106913882ASuitable for intravenous injectionImprove bioavailabilityOrganic active ingredientsPharmaceutical delivery mechanismSolubilityGambogic acid
The invention discloses a polyethylene glycol-gambogic acid liposome, which is composed of a polyethylene glycol-gambogic acid conjugate, polyethylene glycol, vitamin E, cholesterol and phospholipid in a weight ratio of 1-10:0.5-2:0.05-0.2:1-4:10-30. According to the invention, an amphiphilic polymer PEG and an antitumor drug gambogic acid are connected with an ester bond into a conjugate amphipathic PEG-GA, and the PEG-GA is inserted into a liposome bimolecular layer to construct a nano targeted drug delivery system, the water solubility of the drug can be improved, also the drug stability and antitumor effect can be enhanced, drug accumulation in normal tissue can be reduced, the survival time of tumor-bearing mice is prolonged, the treatment efficacy is improved and the toxic and side effects are reduced. The invention also provides a preparation method and application of the liposome, and the liposome can be applied to treatment of lung cancer, ovarian cancer, breast cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma or brain tumors.
Owner:SICHUAN PROVINCIAL PEOPLES HOSPITAL
Method used for differentiating benign tumor and malignant tumor based on infrared light spectrums
ActiveCN108732121AAvoid interferenceAccurate predictionMaterial analysis by optical meansLighting spectrumWilms' tumor
The invention discloses a method used for differentiating benign tumor (pulmonary sclerosing pneumocytoma) and malignant tumor (adenocarcinoma in situ) based on infrared light spectrums. The method comprises following steps: benign tumor and malignant tumor tissue slices are collected, slice infrared transmitted spectrums are collected at 4000 to 1900cm<-1> range at a resolution ratio of 8cm<-1> and scanning time of 64; the obtained spectrums are not subjected to pretreatment, or are subjected to SGS pretreatment, mole construction spectrum range upper limit is determined to be 4000 to 3960cm<-1>, the lower limit is determined to be 1960cm<-1>, the former 4 to 9 main ingredients are selected, discriminant analysis method or counter propagation network are adopted to construct a model usedfor differentiating benign tumor and malignant tumor; a property unknown tumor tissue slice is selected, and spectrum data processing is carried out through the above steps, and at last the constructed model is adopted for prediction. The method can be used for accurate, objective, rapid, and economical differentiating of benign tumor and malignant tumor.
Owner:CHONGQING MEDICAL UNIVERSITY
Application of biomarkers in bile in diagnosis of malignant tumor
PendingCN110129434AEasy to getEfficiently obtainedMicrobiological testing/measurementMedicineBiliary tract
The invention provides an application of reagents for detecting biomarkers in bile in preparation of a tool for diagnosing liver cancer, malignant biliary tract tumors or pancreatic cancer. The invention also provides a tool for diagnosing liver cancer, malignant biliary tract tumors or pancreatic cancer, wherein the tool comprises a reagent for detecting the biomarkers in the bile. The method andtool provided by the invention take the bile as a detection object, has a sample easy to obtain without any adverse effects, and can effectively obtain relevant information involving tumors such as liver cancer, malignant biliary tract tumors or pancreatic cancer.
Owner:埃提斯生物技术(上海)有限公司
Rapid destruction of malignant tumors by excitotoxicity and osmotic-shock medical tactics
ActiveUS9707403B2Quick destructionAvoid structureElectrotherapyArtificial respirationCancer cellMedicine
Owner:NEURO CODE TECH HLDG
Reproducible kidney cancer therapeutic DNA vaccine
InactiveCN103948943AImprove immune efficiencyImprove presentationGenetic material ingredientsAntibody ingredientsKidney cancerA-DNA
The invention discloses a reproducible kidney cancer therapeutic DNA vaccine. The reproducible kidney cancer therapeutic DNA vaccine is obtained by inserting a compound gene sig-tG250-Fc-GPI-IRES-GM / B7 into a reproducible DNA vaccine carrier pSVK. The reproducible kidney cancer therapeutic DNA vaccine is a DNA vaccine capable of inducing self anti-tumor immune response, has good safety and broad application prospect and provides a new method and thinking for prevention and treatment of malignant tumors.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Morusin anti-tumor application
InactiveCN104800204AImprove targetingEasy to operateOrganic active ingredientsAntineoplastic agentsSide effectApoptosis
The invention provides an application of morusin or its pharmaceutically acceptable derivative in preparation of medicines for resisting malignant tumor. The invention also provides an application of morusin or its pharmaceutically acceptable salt in preparation of anti-glioma medicines. It is found through researches that morusin shows a good activity of resisting malignant tumor (such as glioma) in vitro and in vivo. In addition, it shows through experiments that morusin has a good effect of suppressing tumor growth and inducing transversal differentiation and apoptosis of tumor cells and tumor stem cells, and has little toxic and side effect on normal cells. The morusin has a good application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Tripetide boronic acid or boronic ester, preparative method and use thereof
InactiveUS20120135921A1Strong inhibitory activityNervous disorderTetrapeptide ingredientsDiabetes mellitusNervous system
Owner:PEKING UNIV
Mycobacterial immunotherapy for cancer treatment
InactiveUS8557257B2Method securityEffective treatmentBacterial antigen ingredientsBacteria material medical ingredientsEffective treatmentMycobacterium obuense
Owner:ONCOVAC
Medicine for curing malignant tumors of carcinoma of prostate, liver cancer and sarcoma
The present invention relates to a medicine made up by using the Chinese medicinal materials of black nightshade, polyporus, zedoary, ligustrum fruit, vaccaria seed and psoralea seed as main component for curing malignant tumors of prostatic carcinoma, liver cancer and sarcoma, specially for curing prostatic carcinoma. Besides, in said invented medicine one of the Chinese medicinal materials of astragalus root, flowery knotweed root, poria, prunella spike and pangolin scles, etc. or their combination can be added.
Owner:郭应禄 +2
Tyrosine kinase inhibitor and medicinal application thereof in treating malignant tumor
InactiveCN102040588AReduced oxidative metabolismLittle side effectsOrganic active ingredientsOrganic chemistrySide effectTyrosine-kinase inhibitor
The invention relates to compounds capable of serving as tyrosine kinase inhibitors and medicinal application thereof in treating malignant tumor. Compared with the prior art, the oxidative metabolism of the compounds provided by the invention is reduced, and the medicinal power performance is improved; and moreover, the compounds have the advantages of less dosage and small side effects.
Owner:苏州康益明华生物医药科技有限公司
Thiazoleamide compound and medical application thereof in treating malignant tumor
InactiveCN101967142AReduce first pass effectImprove bioavailabilityOrganic active ingredientsOrganic chemistrySide effectMyeloid leukemia
Owner:苏州得普医药科技有限公司
Combined drug for immunotherapy of malignant tumors
ActiveCN110448681AMaintain traitsKeep alivePeptide/protein ingredientsUnknown materialsDendritic cellMalignant Glomus Tumor
The invention discloses a combined drug for immunotherapy of malignant tumors. The combined drug includes a preparation containing interleukin 2, and a preparation containing intestinal probiotics; the pharmacological studies confirm that the combined drug of the present invention has a function of reducing tumor burden and controlling tumor growth, can promote the infiltration of cytotoxic T cells and the differentiation and differentiation of dendritic cells, improve the tumor immune microenvironment, can make up for the deficiency of the interleukin 2 alone in the tumor immune microenvironment, and can be applied to the immunotherapy of various malignant tumors.
Owner:君维安(武汉)生命科技有限公司
Treatment of malignant tumor
The invention provides a technology which utilizes donor lymphocyte infusion and by which malignant tumor can be treated without causing such an adverse effect as graft versus host disease. Thus, a method for the treatment of malignant tumor is provided which comprises performing, in a patient requiring such treatment, donor lymphocyte infusion for the graft versus tumor reaction-based treatment of tumor and then performing radiation treatment, infusion of lymphocytes derived from the host or a third party identical in HLA type to the host, and intra bone marrow-bone marrow transplantation using bone marrow cells derived from the host or a third party identical in HLA type to the host, for the prevention and treatment of the graft versus host disease induced by the donor lymphocyte infusion.
Owner:JIMRO
Traditional Chinese medicine anticancer agent
PendingCN108553615APromote recoveryRestore immune functionFungi medical ingredientsCapsule deliveryMedicinal herbsLymphatic Spread
I study Neijing and Compendium of Materia Medica for many years, screen out natural medicinal materials which grow in China, and develop a special-acting drug-a traditional Chinese medicine anticanceragent which can resist malignant tumors in the middle and advanced stages. The agent is non-toxic, and has special effects on lung, stomach, liver, kidney, heart disease, esophagus, breast, thyroid,cervix, colorectal, leukemia and the like, and cure rate is much higher than 62%. For the human immunodeficiency virus, the agent can reduce a HIV viral load. The mechanism of the agent is to block anenergy source of cancer cells, resist the growth of tumor angiogenesis, enhance immune functions, (devour and destroy heterogeneity in blood), induce tumor cell apoptosis and block oncogene mutationand transcription. If the traditional Chinese medicine anticancer agent is taken, pain, nausea and vomiting are soon alleviated and disappeared. Diet is increased, sleep is improved, physical strengthis increased, and the development of the cancer cells is obviously controlled. A tumor block is softened, shrunk and disappeared. After two to three courses of treatment (three months after one course of the treatment), B-ultrasound or CT are used for re-examination of a patent with fast curative effect, a primary lesion disappears, no metastasis and recurrence occurs, and the patient has good health.
Owner:高良福
Itraconazole applied to treatment of malignant tumor or salt thereof and composition thereof
InactiveCN103044408AExpand anti-tumor spectrumSlow growth rateOrganic active ingredientsOrganic chemistryItraconazoleCytoplasm
The invention relates to itraconazole applied to treatment of gastric cancer, lung cancer and liver cancer, and a composition of the itraconazole. The daily dose of the itraconazole is 0.1-5000mg, and the itraconazole has good curative effect when the daily dose is 200mg. The itraconazole and the composition of the itraconazole disclosed by the invention have the beneficial effects that by subcutaneous injection of the itraconazole solution or the composition, the survival time of high and low-dose groups of SPF-grade Konmin mice that have liver cancer H22 can be prolonged. The itraconazole or the composition of the itraconazole has obvious inbibitional effect on Lewis lung cancer of mice in comparison with the control group according to the influence on subcutaneous tumor of the Lewis lung caner, the growth rate (P(0.01) of the tumor can be slowed down; the size (P(0.01) of the tumor is reduced; and the tumor control rate is respectively 43.0% and 45.6% after the treatment is ended. The itraconazole or the composition of the itraconazole influences positive staining of the human gastric cancer tissue VEGF (Vascular Endothelial Growth Factor) in cell cytoplasm, and the VEGF positive expression of a 0.9% sodium chloride solution group is obviously higher than that of the itraconazole group (P(0.05).
Owner:万礼 +1
Topical drug for treating malignant tumor
InactiveCN105381036AGood curative effectQuick resultsAmphibian material medical ingredientsPowder deliveryCentipedeRegimen
The invention discloses a topical drug for treating malignant tumor. The topical drug is prepared by selecting unprocessed radix aconiti lateralis, spreading hedyotis herb, centipede, toad skin, stiff silkworm, snake slough, zaocys dhumnade, agkistrodon, leech, gadfly, scorpion, ground beeltle, manis pentadactyla, amber, chlorite schist, gecko, nidus vespae, safflower carthamus and angelica sinensis through clinical trial verification. In the composition, the raw materials are in combined action, and the effects of strengthening yang qi and supplementing vital qi, counteracting with toxic substances and removing stasis, tonifying qi and detoxifying, relieving swelling and stopping pain, promoting blood circulation and removing stasis, stimulating the menstrual flow and breaking the stasis, and the like are obtained; the therapeutic effect for treating malignant tumor is good and can be obtained quickly, the treatment course is short, and the use is convenient, safe and reliable; the effect of treating both symptoms and root causes and the purpose of enabling malignant tumor to be difficult to recur after being healed can be achieved.
Owner:张军
SENP1 protein inhibitor and use thereof
InactiveCN104436196APrevent proliferationPromote apoptosisMicrobiological testing/measurementGenetic material ingredientsProtein C inhibitorApoptosis
The present invention relates to an SENP1 protein inhibitor and a use thereof, in particular, the invention relates to an SENP1 protein inhibitor shRNA, a use of the SENP1 protein inhibitor in preparation of drugs for preventing or treating malignant blood tumor, and a use in preparation of drugs for inhibiting the proliferation of malignant blood tumor cells and / or promoting the apoptosis of the malignant blood tumor cells. The invention further relates to a method for screening the drugs for preventing or treating malignant blood tumor.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
Medicinal agent for inhibiting metastasis of malignant tumor
InactiveCN103402542AInhibit transferInhibit or prevent metastasisOrganic active ingredientsNervous disorderLymphatic SpreadVascular endothelium
Owner:NAT CEREBRAL & CARDIOVASCULAR CENT +2
Method for treating malignant tumors by using nickase
InactiveCN107308443AWon't hurtLittle side effectsPeptide/protein ingredientsAntineoplastic agentsCancer cellSide effect
The invention discloses a method for treating malignant tumors by using nickase, belonging to the field of medical technology. According to the invention, malignant tumor cells are treated so as to allow malignant tumor cell tissue to resemble an early-stage malignant tumor; an envelope is formed out of the malignant tumor cell resembling the early-stage malignant tumor, and excision is carried out; and after excision, a tumor sample acquired from the early-stage malignant tumor is subjected to acquisition of malignant tumor cells for sequencing, followed-up calculation and positioning of the recognition sequence of endonuclease so as to complete designing of endonuclease; and the endonuclease enters a body via an in-vivo delivery tool such as a deactivated virus and cleaves malignant tumor promoter at a certain site and sequences at other sites. The method provided by the invention poses no harm to normal cells while killing cancer cells, has little side effect and can realize fixed-point elimination.
Owner:THE FIRST AFFILIATED HOSPITAL OF NANYANG MEDICAL JUNIOR COLLEGE
Soup with effects of strengthening body resistance and eliminating diseases for treating malignant tumors and application of soup
InactiveCN109395023AEffective treatmentDispersion deliveryAnthropod material medical ingredientsDiseaseBarbed Skullcap Herb
The invention discloses soup with the effects of strengthening the body resistance and eliminating diseases for treating malignant tumors and application of the soup. The soup is prepared from 30-150parts of hairyvein agrimony, 20-60 parts of nightshade, 30-100 parts of raw milkvetch roots, 5-15 parts of rhizoma curcumae, 6-30 parts of honeycombs, 5-30 parts of stiff silkworms, 6-20 parts of geckos, 15-60 parts of bittersweet, 10-60 parts of barbed skullcap herb, 3-10 parts of raw liquorice roots and 30-150 parts of oldenlandia diffusa. The soup has the effects of tonifying qi and strengthening the body resistance, activating blood to remove blood stasis, and removing toxins and eliminating stasis, and can effectively treat multiple malignant tumors.
Owner:南通市良春中医药临床研究所门诊部有限公司
Nutritional food for patients receiving radiation treatment of malignant tumor
InactiveCN101971976BSuitable for mass productionSimple compositionFood preparationMedicineTherapeutic intent
Owner:山西振东五和医养堂股份有限公司
Digestive system malignant tumor marker, and method for preparing drugs for restraining digestive system malignant tumors
ActiveCN110042160AHigh sensitivityStrong specificityOrganic active ingredientsMicrobiological testing/measurementIn vivoLuminescence
The invention belongs to the biopharmaceutical field, and particularly relates to a digestive system malignant tumor marker, and a method for preparing drugs for restraining digestive system malignanttumors. HYAL2 is used for clinical diagnosis of the digestive system malignant tumors, luminescence quantification PCR is used for detecting the expression situation in the digestive system malignanttumors, and according to the expression situation, HYAL2 is used as a molecule maker for the early diagnosis of the digestive system malignant tumors. A carrier for interference HYAL2 gene expressionis constructed for the drugs for restraining the digestive system malignant tumors. The constructed carrier is used for preparing the drugs for in vitro application or in vivo application. Massive experiment data proves that the HYAL2 exerts important adjusting and controlling effects in the generation and development process of the digestive system malignant tumors, the interference HYAL2 gene expression can notably restrain the proliferation and the migration of digestive system malignant tumor cells, and the HYAL2 is hopeful to prepare a new drug for preventing and treating the digestive system malignant tumors.
Owner:HENAN UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com